Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$182.34 USD

182.34
1,025,151

-2.45 (-1.33%)

Updated Jun 17, 2026 04:00 PM ET

After-Market: $182.38 +0.04 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Understanding Charles River (CRL) Reliance on International Revenue

by Zacks Equity Research

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Zacks Equity Research

CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up

by Zacks Equity Research

Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 13.59% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's How Charles River is Placed Just Ahead of Q1 Earnings

by Zacks Equity Research

CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.

Zacks Equity Research

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?

by Zacks Equity Research

Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.